60 Degrees Pharmaceuticals, Stock Performance
| SXTPW Stock | 0.04 0.01 30.43% |
60 Degrees holds a performance score of 16 on a scale of zero to a hundred. The firm owns a Beta (Systematic Risk) of -8.66, which signifies a somewhat significant risk relative to the market. As returns on the market increase, returns on owning 60 Degrees are expected to decrease by larger amounts. On the other hand, during market turmoil, 60 Degrees is expected to outperform it. Use 60 Degrees Pharmaceu standard deviation and the relationship between the value at risk and market facilitation index , to analyze future returns on 60 Degrees Pharmaceu.
Risk-Adjusted Performance
16 of 100
Weak | Strong |
Solid
Compared to the overall equity markets, risk-adjusted returns on investments in 60 Degrees Pharmaceuticals, are ranked lower than 16 (%) of all global equities and portfolios over the last 90 days. In spite of fairly inconsistent basic indicators, 60 Degrees showed solid returns over the last few months and may actually be approaching a breakup point. ...more
1 | 60 Degrees Pharmaceuticals, Inc. Sees Large Growth in Short Interest - Defense World | 07/26/2024 |
2 | Should You Add 60 Degrees Pharmaceuticals, Inc. to Your Stock Portfolio Right Now - Yahoo Finance | 08/12/2024 |
3 | 60 Degrees Pharmaceuticals, Inc. Regains Compliance with Nasdaq Listing Requirements - GlobeNewswire | 08/28/2024 |
4 | 60 Degrees Pharmaceuticals Inc. Announces ARAKODA Promotional Pilot in Advance of Expanded U.S. Launch - Marketscreener.com | 10/03/2024 |
5 | 60 Degrees Pharmaceuticals Expands Tafenoquine Clinical Trial for Babesiosis to Brigham and ... | 12/11/2024 |
| Begin Period Cash Flow | 264.9 K |
SXTPW |
60 Degrees Relative Risk vs. Return Landscape
If you would invest 4.07 in 60 Degrees Pharmaceuticals, on September 16, 2024 and sell it today you would lose (0.17) from holding 60 Degrees Pharmaceuticals, or give up 4.18% of portfolio value over 90 days. 60 Degrees Pharmaceuticals, is currently producing 12.3996% returns and takes up 57.6979% volatility of returns over 90 trading days. Put another way, most equities are less risky on the basis of their return distribution than SXTPW, and majority of traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
60 Degrees Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for 60 Degrees' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as 60 Degrees Pharmaceuticals,, and traders can use it to determine the average amount a 60 Degrees' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.2149
| Best Portfolio | Best Equity | SXTPW | ||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 57.7 actual daily | 96 96% of assets are less volatile |
Expected Return
| 5.01 actual daily | 96 96% of assets have lower returns |
Risk-Adjusted Return
| 0.21 actual daily | 16 84% of assets perform better |
Based on monthly moving average 60 Degrees is performing at about 16% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of 60 Degrees by adding it to a well-diversified portfolio.
60 Degrees Fundamentals Growth
SXTPW Stock prices reflect investors' perceptions of the future prospects and financial health of 60 Degrees, and 60 Degrees fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on SXTPW Stock performance.
| Revenue | 253.57 K | ||||
| EBITDA | (2.11 M) | ||||
| Net Income | (3.77 M) | ||||
| Total Debt | 8.77 K | ||||
| Cash Flow From Operations | (4.54 M) | ||||
| Total Asset | 7.78 M | ||||
| Retained Earnings | (32.58 M) | ||||
About 60 Degrees Performance
Evaluating 60 Degrees' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if 60 Degrees has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if 60 Degrees has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
60 Degrees is entity of United States. It is traded as Stock on NASDAQ exchange.Things to note about 60 Degrees Pharmaceu performance evaluation
Checking the ongoing alerts about 60 Degrees for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for 60 Degrees Pharmaceu help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| 60 Degrees Pharmaceu is way too risky over 90 days horizon | |
| 60 Degrees Pharmaceu has some characteristics of a very speculative penny stock | |
| 60 Degrees Pharmaceu appears to be risky and price may revert if volatility continues | |
| 60 Degrees Pharmaceu has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the revenue of 253.57 K. Net Loss for the year was (3.77 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| 60 Degrees generates negative cash flow from operations | |
| 60 Degrees Pharmaceu has a very weak financial position based on the latest SEC disclosures | |
| Latest headline from gurufocus.com: 60 Degrees Pharmaceuticals Expands Tafenoquine Clinical Trial for Babesiosis to Brigham and ... |
- Analyzing 60 Degrees' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether 60 Degrees' stock is overvalued or undervalued compared to its peers.
- Examining 60 Degrees' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating 60 Degrees' management team can have a significant impact on its success or failure. Reviewing the track record and experience of 60 Degrees' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of 60 Degrees' stock. These opinions can provide insight into 60 Degrees' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for SXTPW Stock Analysis
When running 60 Degrees' price analysis, check to measure 60 Degrees' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy 60 Degrees is operating at the current time. Most of 60 Degrees' value examination focuses on studying past and present price action to predict the probability of 60 Degrees' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move 60 Degrees' price. Additionally, you may evaluate how the addition of 60 Degrees to your portfolios can decrease your overall portfolio volatility.